• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Ken time to clean ur house....it's embarrassing

Quote
Anonymous said:
Actually, I beg to disagree a bit. Many people hired ago were best in class at the time because a lot of the industry was still developing. While the rest of the industry learned, experimented, and took risks, many of those same people hired 20 and 30 years ago are still at Merck. They rose to high levels but have not learned anything new.

Any time someone came from the outside with new ideas, they were simply quashed as "not being the Merck way". Well the Merck way, managed by old-schoolers is way old. bureaucratic, and so scared of taking any risks. What a shame
Click to expand...

30 years ago the culture was different than today. Most of the R&D old schoolers are gone. They could not adapt to the new way of doing business. I actually don't blame them. They were not hardwired to deal with this crap. They were extremely intelligent but had no social game. Back then you did not need one. They knew what the job was and they did it well. The Merck way now is not the old Merck way. They were very passionate and always cutting edge. If they were still here our pipeline would still be full. The big difference is the current management can only do things the old way because they don't have the vision to think of anything new. Everything is ran by fear and intimidation rather than free thinking with being able to give an opinion independent of authority. Why do you think we get trumped by such smaller companies now.
 




Didn't you guys see the post "in the spotlight"? and the link:http://www.canada.com/McGill+Univer...published+falsified+images/7889807/story.html
reporting Merck executive Donald Nicholson and his former postdoc Maya Saleh, cheating in their publications? If they cheat in their publications, chances are they also cheat at work. Merck is probably loaded with executives who cheat to get ahead---that's what the Merck board needs to clean up. Donald Nicholson originally came from Merck Frosst, and when after the merger with SP Merck closed that shop in late 2010 early 2011, most of the leaders were transferred to NJ research centers. My question: How many more of these leaders from Merck Frosst are cheaters? Isn't frightening that they are leading the R&D efforts. Who are responsible for populating R&D at Merck with cheaters? Ultimately Ken, more likely Kim, his Franchise head and other hench men who thought Merck Frosst was gold? Fools gold!
 




Anonymous said:
Time to clean out Ken...watch the video, he's an embarrassment to anyone in this business.
Click to expand...

We are heading south fast....

Mark Schoenebaum, at ISI Group, conducted an anonymous poll of his clients following the announcement. The buy-siders called for executive scalps. One called the conference call “horrible” and intoned, “management must change or they will be changed.” Another wrote: “Management has its head in the sand,” and added that Merck needs to streamline R&D and move away from diseases like osteoporosis and heart disease that require big outcome trials. “Why is Peter Kim still there?” wrote one. Another said Kim “must step down.” This poll of investors only gave a 50% chance that odanacatib will be approved by 2015
 




Anonymous said:
We are heading south fast....

Mark Schoenebaum, at ISI Group, conducted an anonymous poll of his clients following the announcement. The buy-siders called for executive scalps. One called the conference call “horrible” and intoned, “management must change or they will be changed.” Another wrote: “Management has its head in the sand,” and added that Merck needs to streamline R&D and move away from diseases like osteoporosis and heart disease that require big outcome trials. “Why is Peter Kim still there?” wrote one. Another said Kim “must step down.” This poll of investors only gave a 50% chance that odanacatib will be approved by 2015
Click to expand...

Kim is only a small part of the issue. There are major problems from top to bottom. Even the lowest people suck.
 








in search of truth lets see how it aligns with what Peter Kim said on the conference call....
Peter S. Kim, Ph.D. - EVP and President, Merck Research Laboratories: Thank you, Ken. Good morning, everyone. As you will recall, last July, the Data Monitoring Committee for refractory trial recommended the pivotal study be closed and the extension study, which includes more than 8,000 women continue.

We have just recently received data from the pivotal study, but do not have data from on the ongoing extension trial. We have decided to include data from the extension study in our filings for regulatory approvals. The extension study is double-blinded, patients and investigators are blinded. Our plans to present the data are dependent on our need to maintain the blind in order to file. Therefore, we do not intend to present the results of the pivotal study and we do not intend to provide additional information on safety or efficacy until after we've locked the database for the filings.

We will then present the data in an appropriate scientific meeting. Let me underscore that we continue to believe in the potential of odanacatib to address unmet medical needs for patients with osteoporosis and look forward to filing in 2014. Ken?
 




Old Merck guy here. I left when I saw good people being dumped, bullied and intimidated by disconnected management. I agree with the old saying that corporate business is like a stew...it should be stirred often to keep the scum from rising to the top. Any of us older folks know that in this business crap ALWAYS starts at the top. Merck was a respected company that treated people with some dignity. From what I hear now, it's nothing compared to what it was. It's frustrating to work with the feeling that each day could be your last. Merck has completely lost touch with that simple concept. Reps will leave and inexperienced kids will be brought in and wonder why they fail with no training and unrealistic expectations. I would encourage anyone to look elsewhere...the days of being a Pharma rep are over.
 




Anonymous said:
in search of truth lets see how it aligns with what Peter Kim said on the conference call....
Peter S. Kim, Ph.D. - EVP and President, Merck Research Laboratories: Thank you, Ken. Good morning, everyone. As you will recall, last July, the Data Monitoring Committee for refractory trial recommended the pivotal study be closed and the extension study, which includes more than 8,000 women continue.

We have just recently received data from the pivotal study, but do not have data from on the ongoing extension trial. We have decided to include data from the extension study in our filings for regulatory approvals. The extension study is double-blinded, patients and investigators are blinded. Our plans to present the data are dependent on our need to maintain the blind in order to file. Therefore, we do not intend to present the results of the pivotal study and we do not intend to provide additional information on safety or efficacy until after we've locked the database for the filings.

We will then present the data in an appropriate scientific meeting. Let me underscore that we continue to believe in the potential of odanacatib to address unmet medical needs for patients with osteoporosis and look forward to filing in 2014. Ken?
Click to expand...

What is really embarrassing is that Merck actually thinks it has a R&D department.
 




Hey kenny boy how is KFC ONE doing expense wise? I see you flying over all the time and can only humm the jeffersons theme song "moving on up" . Just wish the company was moving on up!
 




Years ago no one would have expressed that Merck was a toxic place at which to work. Now that is a feeling commonly held by dare I say....a majority of Merck employees across all divisions/departments. The feeling of antagonism and hostility from management toward the rank and file is paralyzing.
 




Anonymous said:
this even a better post from someone who loves to pick on merck because he thinks we are stupid and easy to poke fun at....

http://www.forbes.com/sites/matthewherper/2013/02/08/merck-delay-draws-wall-street-ire/
Click to expand...

Thank you for posting the link. I love the following paragraph from the forbes article.

"Mark Schoenebaum, at ISI Group, conducted an anonymous poll of his clients following the announcement. The buy-siders called for executive scalps. One called the conference call “horrible” and intoned, “management must change or they will be changed.” Another wrote: “Management has its head in the sand,” and added that Merck needs to streamline R&D and move away from diseases like osteoporosis and heart disease that require big outcome trials. “Why is Peter Kim still there?” wrote one. Another said Kim “must step down.” This poll of investors only gave a 50% chance that odanacatib will be approved by 2015."

You know your executive leadership sucks when investors are ripping on them and asking for specific executives to be fired. The good news is some at the top may leave but the bad news is that they will leave with golden parachutes at the rest of our expense.
 




Anonymous said:
Hey kenny boy how is KFC ONE doing expense wise? I see you flying over all the time and can only humm the jeffersons theme song "moving on up" . Just wish the company was moving on up!
Click to expand...

KFC one should be cut from the budget - ridiculous as his the fact that kenny has someone in his exec bathroom to warm the hand towels and make sure there is blue ice in his toilet. Really? what is this a resort?
 




Anonymous said:
“Why is Peter Kim still there?” wrote one. Another said Kim “must step down.” This poll of investors only gave a 50% chance that odanacatib will be approved by 2015."

You know your executive leadership sucks when investors are ripping on them and asking for specific executives to be fired. The good news is some at the top may leave but the bad news is that they will leave with golden parachutes at the rest of our expense.
Click to expand...

Trust me, they have been trying to replace Peter Kim for a long time. The fact that he decimated the upper ranks early on ensured that he has no viable internal succession candidates. As for outside candidates, just who of any stature would want to have Kim's job? Who would want to clean up Peter Kim's disaster? No amount of money is worth the headaches and heartaches that a real restructuring would entail from a stable human being. Perhaps there are other rich, demented sociopaths out there like Peter Kim who would take the job, but Merck does not need more of the same horrible, dysfunctional management.
 




Anonymous said:
Trust me, they have been trying to replace Peter Kim for a long time. The fact that he decimated the upper ranks early on ensured that he has no viable internal succession candidates. As for outside candidates, just who of any stature would want to have Kim's job? Who would want to clean up Peter Kim's disaster? No amount of money is worth the headaches and heartaches that a real restructuring would entail from a stable human being. Perhaps there are other rich, demented sociopaths out there like Peter Kim who would take the job, but Merck does not need more of the same horrible, dysfunctional management.
Click to expand...

Who would want to head such a screwed up group. It's bad from top to bottom. In the state it's in removing him would not even scratch the surface. It's so beyond that.
 




At the end of the day it's simple. We are going to have 2 more minor patents expire this year also. If research and development does not get straightened out there is a world of hurt coming. Right now we are worth around 125 billion. Investors are now getting jittery with good cause. If we continue course, in 3 years we should be in the 60-70 billion range. If we have anything promising we might get bought by another company. That's a best case situation. Worse case is we get taken off the public market by venture capitalists thinking they can turn things around. If that happens everything is on the table. Nothing is reported and nothing is out of reach. If people think a merger is bad, it is nothing compared to a public company going private. The employees, benefits, and pensions are put through a shredder. It's a horrible thing.
 




Anonymous said:
At the end of the day it's simple. We are going to have 2 more minor patents expire this year also. If research and development does not get straightened out there is a world of hurt coming. Right now we are worth around 125 billion. Investors are now getting jittery with good cause. If we continue course, in 3 years we should be in the 60-70 billion range. If we have anything promising we might get bought by another company. That's a best case situation. Worse case is we get taken off the public market by venture capitalists thinking they can turn things around. If that happens everything is on the table. Nothing is reported and nothing is out of reach. If people think a merger is bad, it is nothing compared to a public company going private. The employees, benefits, and pensions are put through a shredder. It's a horrible thing.
Click to expand...

All those brilliant people who work here in science and business. How could they let this happen? Did they ignore the signs? Did they just keep rolling along without care about tomorrow? It almost sounds like the government...spending, spending, spending without real care about tomorrow....poor administrative planning, poor business planning.....

Makes all those brilliant people look dumb. Dont you think?
 




Anonymous said:
All those brilliant people who work here in science and business. How could they let this happen? Did they ignore the signs? Did they just keep rolling along without care about tomorrow? It almost sounds like the government...spending, spending, spending without real care about tomorrow....poor administrative planning, poor business planning.....

Makes all those brilliant people look dumb. Dont you think?
Click to expand...

I they were so brilliant we would be in this situation. Our scientists are sub-par at best. This didn't happen overnight. It took 10 years to get here. Post 21 hit the nail on the head.
 












Management is a complete joke, especially the pit bosses. The CTL and DCOS are cooked, they are unable to even get rep jobs. Talk about white knuckling it. It is sad talking to those who I used to work with and failed to move on. They are very desperate people, one I know works at lowes at the return desk- seriously!
 




Top Bottom
Back
Quote